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Objective: Previously, it has been shown that KIF14 mRNA is overexpressed in ovarian cancer (OvCa), regardless of
histological subtype. KIF14 levels are independently predictive of poor outcome and increased rates of recurrence in
serous OvCa patients. Furthermore, it has been shown that KIF14 also controls the in vivo tumorigenicity of OvCa
cell lines. In this study, we evaluate the potential of KIF14 as a therapeutic target through selective inhibition of
KIF14 in primary high-grade serous patient-derived OvCa cells.
Methods: To assess the dependence of primary serous OvCa cultures on KIF14, protein levels in 11 prospective high
grade serous ovarian cancer samples were increased (KIF14 overexpression by transfection) or decreased (anti-KIF14
shRNA) in vitro, and proliferative capacity, anchorage independence and xenograft growth were assessed.
Results: Seven of eleven samples demonstrated increased/decreased in vitro proliferation in response to KIF14
overexpression/knockdown, respectively. When examining in vitro tumorigenicity (colony formation) and in vivo growth
(subcutaneous xenografts) in response to KIF14 manipulation, none of the samples demonstrated growth in soft agar
(11 samples), or xenograft growth (4 samples).
Conclusions: Although primary high-grade serous OvCa cells may depend on KIF14 for in vitro proliferation we were
unable to demonstrate a role for KIF14 on tumorigenicity or develop an in vivo model for assessment. We have,
however developed an effective in vitro method to evaluate the effect of target gene manipulation on the
proliferative capacity of primary OvCa cultures.
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Located on chromosome 1q32, KIF14 has been demon-
strated to be overexpressed at the genomic and gene ex-
pression levels in multiple cancers, including breast and
retinoblastoma [1], liver [2], renal papillary [3], lung [4],
and ovarian cancers (OvCas) [1,5-11]. Comparative gen-
omic hybridization (CGH) studies determined in breast,
ovarian, prostate, oesophageal, multiple myeloma and
hepatocellular carcinomas that gain in chromosome
1q32 correlated highly with recurrence and poor differ-
entiation, and this gain has been postulated as an early
or initiating event [12-18].* Correspondence: marcus.bernardini@uhn.ca
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unless otherwise stated.KIF14 has been shown to be essential for the final phase
of cytokinesis [19,20]. A molecular motor and microtubule-
associated protein, KIF14 was shown to interact directly
with Protein regulating cytokinesis 1 (PRC1) and Citron
kinase (CIT), displaying a central organizing role in cyto-
kinesis [19]. High KIF14 mRNA expression is documented
in many cancers including hepatocellular [2,21,22] and la-
ryngeal carcinomas [23], while KIF14 expression levels
correlate with adverse features in papillary renal tumors
[3] and pancreatic carcinomas [24]. Furthermore, KIF14
expression has been associated with chemoresistance in
triple-negative breast cancers [25,26]. We have previously
shown prognostic significance of KIF14 mRNA in breast,
lung and ovarian cancers [5,27,28] and uncovered tran-
scriptional and epigenetic regulation of KIF14 overexpres-
sion in ovarian cancers [29].
KIF14 is overexpressed in the majority of primary OvCa
tumors regardless of stage. Close to 30% of serous OvCasal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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KIF14 overexpression, suggesting that KIF14 gain, when
present, may be an early event in the development of
serous OvCa [5]. KIF14LOW serous patients demonstrate a
significant survival advantage over KIF14HIGH patients en-
forcing the predictive value of KIF14 expression for out-
come of serous OvCa patients [5]. Previously, it has been
shown that overexpression of KIF14 in OvCa cell lines sig-
nificantly increased proliferation and the number of soft
agar colonies. KIF14 knockdown in the same immortal-
ized cell lines showed reduced proliferation, increased
apoptosis, and most importantly, significantly reduced col-
ony formation to a greater extent than proliferation [5].
Since KIF14 displays a favourable therapeutic ratio (very
low expression in adult tissues), knowledge of the exact
function(s) of KIF14 in the progression of OvCa may de-
fine an important therapeutic target. To conclusively dem-
onstrate the importance of KIF14 in promoting OvCa and
to develop KIF14 overexpression as a “high risk” marker
for OvCa, the next step was to study the implications of
KIF14 expression in the progression of primary OvCa tu-
mors derived from patients. In this study, we evaluated
the potential of selective KIF14 overexpression or inhib-
ition in primary high-grade serous patient-derived OvCa
cells.Materials and methods
Clinical samples
Thirty fresh high-grade serous ovarian tumor samples
were obtained from OvCa patients admitted to the
Gynecological Oncology Clinic, Princess Margaret Hospital,
Toronto, ON. Tumor samples (or ascites fluid) were col-
lected at initial debulking surgery, prior to administra-
tion of chemotherapy, and released by the University
Health Network (UHN) Biobank, Toronto, ON. The UHN
Research Ethics Board approved this study, and all tissues
were banked with written informed consent. All UHN
Biobank tissues (adjacent H and E stained slides) were
reviewed by a gynecologic pathologist (PAS) to ensure that
released tissues were of high-grade serous histology, and
contained >80% tumor cells.Primary derivative cultures of OvCa tissues
Samples destined for derivative cultures were immediately
taken to the laboratory where a small portion was reserved
for RNA and DNA isolation, and the remainder cultured
as previously described and commonly performed in our
laboratory [30]. Early-passage cells (passages 2–5) were
employed for our analyses, to avoid the induction of gen-
omic changes due to culture adaptation. This culture time
was sufficient to obtain cells for KIF14manipulations (yield
of several million cells within 2–3 passages) [30,31]. We
obtained 29 primary samples from the UHN Biobank.From these, we were able to develop short-term in vitro
derivative cultures from 11 tumor samples.
RNA extraction and reverse transcription
Total RNA was extracted from primary tissues and cells by
homogenizing tissue through a syringe in TRIzol reagent
(Invitrogen, Mississauga, ON), followed by chloroform ex-
traction and isopropanol and ethanol precipitations. One
microgram of total RNA was used in reverse transcription
(RT) reactions, as previously described [5]. To confirm RT,
1 L of each reaction was tested in endpoint PCR for KIF14
and the housekeeping gene HPRT (hypoxanthine phos-
phoribosyl transferase) as described [5].
End-point and real-time PCR
For end-point PCR, 1 μL of the RT reaction was added
to a 25 μL PCR reaction containing 0.5 U Hot Start Taq
Polymerase (Fermentas, Burlington, ON), 0.2 mM dNTPs,
1.5 mM MgCl2 and KIF14 primers; cycling conditions
were previously described [5]. TBP was used as an en-
dogenous control, and products were visualized by gel elec-
trophoresis and ethidium bromide staining.
For real-time PCR, RT reaction products were di-
luted 10-fold with RNAse/DNAse-free ddH2O, and 1.5 L
was added to 1X TaqMan PCR master mix (Applied
Biosystems, Life Technologies, Carlsbad, CA) and 1X
TaqMan Gene Expression Assay primer-probe mix for
KIF14 (Hs00978216_m1). Mean expression of three
housekeeping genes was used as an endogenous control:
TBT (Tata-box binding protein, Hs_99999910_m1), HPRT
(Hypoxanthine phosphoribosyl transferase, Hs_99999909_
m1), and GAPDH (glyceraldehyde-3-phosphate dehydro-
genase, Hs_99999905_m1), due to their stable expression
in primary OvCa tumor tissues [5]. Triplicate reactions
were conducted for each gene and each tissue sample, and
PCR performed using the SDS 7900HT system as de-
scribed [5]. SDS 2.1 Software (ABI) was used to calculate
Ct relative expression values, normalized to endogenous
control genes, and relative to either untreated, scrambled
or empty-vector controls.
Established cell line culture, shRNA lentivirus
construction, transductions and transfections
SKOV3 and OvCa429 cells (a kind gift from Dr. Mark
Nachtigal, University of Manitoba, Winnipeg, MB) were
grown in DMEM H16 minimal medium (SKOV3) or
alpha-MEM (OvCa 429) supplemented with penicillin-
streptomycin and 10% fetal bovine serum at 37°C, 5%
CO2 in a humidified chamber. Packaging cells (293FT,
Invitrogen) were grown as SKOV3 cells. All parental and
derived stable cell lines were authenticated using STR
(short tandem repeat) profiling (The Centre for Applied
Genomics, Hospital for Sick Children, Toronto, ON).
Anti-KIF14 shRNA lentiviruses were generated by co-
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ing puromycin resistance, targeting human KIF14 (5 sep-
arate constructs, #816-819 plus a Scrambled control;
Sigma-Aldrich) with packaging constructs pPAX2 and
pMD2G (a kind gift from Dr. Jason Moffat, University of
Toronto, Toronto, ON) in 293FT cells using Gene Juice
(EMD Biosciences, Gibbstown, NJ) according to manu-
facturer instructions. Virus supernatant was harvested
48 h post-transfection and concentrated 10-fold using the
LentiX viral concentrator solution (Clontech Laboratories,
Mountain View, CA). KIF14 knockdown in primary
OvCa cultures and cell lines was confirmed 72 h post-
transduction using real-time PCR and western blot (WB)
analyses. Overexpression of KIF14 was generated by trans-
fection of KIF14-EGFP (a kind gift from Dr. Francis
Barr, Max Planck Institute of Biochemistry, Martinsreid,
Germany) or pcDNA 3.1 expressing neomycin resistance
(empty vector control). Transfections were conducted
with Turbofect in vivo transfection reagent (Fermentas)
according to manufacturer’s instructions. WB analysis was
performed by probing with a polyclonal rabbit anti-KIF14
antibody (1:500, Bethyl Laboratories, Montgomery, TX)
or anti-EGFP antibodies (1:2000, Abcam, Cambridge,
MA) normalized to β-tubulin (1:1000, Sigma-Aldrich).
Horseradish peroxidase-labeled secondary antibodies (1:10,000,
Chemicon, Billerica, MA) were detected using a chemilu-
minescence reagent (Denville Scientific, Metuchen, NJ)
and incubated with photographic film (Denville).Immunofluorescence
Cells were stained with a polyclonal rabbit anti-KIF14
antibody (Bethyl Laboratories), followed by a mouse anti-
rabbit Alexa 488 secondary antibody (Molecular Probes,
Mississauga, ON), and nuclei visualized by DAPI staining
(Sigma-Aldrich). Stained cells were visualized at a magnifi-
cation of up to 400X with an epifluorescence microscope
(Leica, Wetzlar, Germany).Proliferation and soft-agar colony forming assays
Proliferation was measured by surrogate intracellular
ATP readings using a commercially available assay kit
(Cell TiterGlo; Promega) according to manufacturer’s in-
structions. Cells were seeded in triplicate at 5000 cells/
96-well dish (Day 0) and counted every 2 to 3 days for
up to 12 days. Colony assays were conducted by seeding
cells in triplicate at 1 × 104 cells (primary OvCa cells) or
1 × 103 cells (OvCa cell lines)/6-well dish in 0.3% noble
agar, atop a plug of 0.6% noble agar in growth medium
(Biorad Laboratories, Mississauga, ON). After 14 (OvCa
cell lines) or 30 days of growth, colonies were stained
with crystal violet and counted with the 1.5X objective
of a dissecting microscope (Leica). All experiments were
conducted on three separate occasions in triplicate.Subcutaneous xenografts
Female NOD-SCID gamma mice were injected subcuta-
neously into the flank with 1 million cells mixed at a 1:1
ratio with Matrigel (BD Biosciences, Mississauga, ON) in
a 200 L total volume. Four primary OvCa samples that
were manipulated for either overexpression or knock-
down, plus their respective control cells were injected into
triplicate mice, and monitored for a total of 6 months for
appearance of tumors. These mice were studied using pro-
tocols approved by the Animal Care Committee of the
Ontario Cancer Institute, in accordance with Canadian
Council on Animal Care guidelines.
Statistical analyses
Unpaired t-tests were performed to determine statistical
differences (where significance < 0.05) between cell num-
ber in response to KIF14 manipulation (overexpression
or knockdown) relative to the control cells (empty vec-
tor or scrambled control) using Graph Pad Prism 4.0.
Results
Short-term culture of primary high-grade serous OvCa
cells reduces endogenous KIF14 levels
We obtained 29 high-grade serous primary samples from
the UHN Biobank. From these, we were able to develop
short-term in vitro derivative cultures from 11 tumor sam-
ples. These 11 samples were then further characterized for
KIF14 expression.
To determine whether the expression of KIF14 varied
with adaptation to culture, KIF14 mRNA was measured
in primary tissues and short-term primary OvCa cultures
(passage 3) using real-time PCR. As depicted in Figure 1,
45% of the primary tumor tissues tested (5 out of 11; dark
blue) exhibit very high KIF14 expression in comparison
with previously characterized KIF14HIGH and KIF14LOW
primary OvCa tumors [5], and would belong to the
KIF14HIGH expressers group, while the remaining 55%
of samples (6 out of 11) would be grouped into the
KIF14LOW expressers group. For most primary samples
however (9 out of 11), short-term adaptation to culture
(approximately 3 weeks) did significantly decrease KIF14
expression (2 to 5-fold decrease; Figure 1). One sample
(69719) did not exhibit any change in KIF14 expression,
while one sample (69639) showed an increase in KIF14 ex-
pression in response to in vitro culture conditions.
Primary high-grade serous OvCa cells depend upon KIF14
expression for proliferation
To test whether primary OvCa cells are dependent upon
KIF14 expression for their tumorigenicity, 11 samples
were transduced with an anti-KIF14 shRNA lentivirus
(LV-816 plus a scrambled control). We observed expres-
sion of KIF14 protein via immunofluorescence (Additional
file 1: Figure S1); a significant decrease in KIF14 protein
Figure 1 KIF14 mRNA expression in response to short-term in vitro culture conditions. Eleven primary OvCa samples (high-grade serous
histology) were measured for KIF14 expression in the primary tissue (dark blue) and in short-term culture (passage 3, light blue). Previously
characterized KIF14HIGH and KIF14LOW primary OvCa samples (5) were included as controls. Error bars represent standard deviation of 3
independent measurements for each sample.
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sages) in most cells. KIF14 mRNA expression was also
measured in these samples after 21 days (5 passages) of
culture via real-time PCR. A significant decrease in KIF14
expression was seen in all transduced samples (2 to 5-fold,
Figure 2).
The growth properties of these 11 primary OvCa sam-
ples were measured in response to KIF14 knockdown via
cellular ATP. Most samples (7 out of 11, 64%) demon-
strated a significant decrease in cell proliferation in re-
sponse to KIF14 knockdown (P < 0.05; Figure 3). However,
a smaller percentage of samples (4 out of 11, 36%) showedFigure 2 KIF14 knockdown in primary OvCa samples. Eleven
primary OvCa samples were transduced with lentivirus expressing
anti-KIF14 shRNA (LV-816) (green), and mRNA expression measured
21 days (passage 5) post-transduction in comparison to a scrambled
shRNA control (control; blue). KIF14 expression in LV-816 cells
normalized to control cell expression (set as 1). Error bars represent
standard deviation of three independent experiments.no significant change in proliferation even when KIF14
was reduced (P > 0.01; Figure 3).
Overexpression of KIF14 increases the proliferative
capacity of primary high-grade serous OvCa cells
To study the consequence of KIF14 overexpression on
the tumorigenic phenotype of closely derived patient
samples, short-term cultures KIF14HIGH or KIF14LOW
OvCa cells were engineered to overexpress KIF14 via
transient transfection of an EGFP-tagged KIF14 cDNA
plasmid [19]. We observed strong expression of KIF14-
EGFP in most cells after 14 days post-transfection (3
passages; Additional file 2: Figure S2). Overexpression of
KIF14 mRNA was also seen in all samples for at least
21 days post-transfection (Figure 4).
We measured the growth properties of these 11 primary
OvCa samples in response to KIF14 overexpression via
cell proliferation assays. The majority of samples (7 out
of 11, 64%) demonstrated a significant increase in cell
proliferation in response to KIF14 overexpression (P < 0.05;
Figure 3), while a smaller percentage of samples (4 out
of 11, 36%) showed no significant change in proliferation
(P > 0.01; Figure 3).
Survival of primary high-grade serous OvCa cells is
impaired under in vitro or in vivo anchorage-independent
conditions
We evaluated in vitro anchorage independence via growth
in soft agar. Unfortunately, none of the 11 primary sam-
ples grew under these conditions (whether transfected
with KIF14-EGFP, transduced with LV-816, or their con-
trol counterparts (empty vector or scrambled control)), in
comparison to the immortalized OvCa cell line SKOV3
Figure 3 The effect of KIF14 overexpression/knockdown on primary OvCa cultures. Cell viability readings in response to KIF14 overexpression
(KIF14, dark blue) or KIF14 knockdown (LV-816, light blue) relative to their respective controls (pcDNA (KIF14), dark red; SCR (LV-816), light red). *P <0.05.
Error bars represent standard deviation of 3 independent experiments.
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Figure 4 KIF14 overexpression in primary OvCa samples. Eleven
primary OvCa samples were transiently transfected with KIF14-EGFP
(red), and mRNA expression measured 21 days (passage 5)
post-transfection in comparison to the empty vector control
(pcDNA; blue). KIF14 expression in KIF14-EGFP cells normalized to
control cell expression (set as 1). Error bars represent standard
deviation of three independent experiments.
Figure 5 Colony assays. A Representative primary OvCa short-term cultur
control vector (middle) or overexpressing KIF14 (bottom panels). Images ta
control vectors (pcDNA or SCR), overexpressing KIF14 (SKOV3_KIF14) or
seeding. Magnification, 20X.
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soft agar assay is 14–30 days), however no growth was
seen in the 11 primary samples even after this extended
growth period.
For evaluation of in vivo growth, we chose 4 primary
OvCa samples that demonstrated the highest overexpres-
sion and increase in proliferation (and the greatest decrease
in expression/proliferation) in response to KIF14 overex-
pression (or knockdown; samples 6972, 6973, 63639;
Figure 3). We injected 1 million cells mixed with matrigel
subcutaneously into NOD-SCID gamma (NSG) mice, and
monitored growth over a 6 month period. Unfortunately,
mirroring the results seen in soft agar, none of the 4 sam-
ples tested demonstrated any growth, including the cells
overexpressing KIF14.
Discussion
The prognostic potential of KIF14 expression in OvCa [5]
suggests a dependence on KIF14 for tumorigenic behav-
iour. If high KIF14 expression is sufficient to alter primary
OvCa cell behaviour in vitro and in vivo, an oncogenic
stimulus would be identified in OvCa, providing proof-ed sample (6972) grown in soft agar either untreated (top), expressing
ken 2 and 30 days post seeding. B SKOV3 cells expressing either
knocked-down in KIF14 (SKOV3_LV-816). Images taken 14 days post
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nisms. Seven out of the 11 samples tested demonstrated
increased/decreased proliferation in response to KIF14
overexpression/knockdown, indicating a dependence upon
KIF14 expression to maintain proliferative capacity. Four
out of the 11 samples did not show a phenotypic response
despite the fact that all samples showed significant overex-
pression of KIF14 post-transfection, even after 21 days in
culture (Figure 4). These results raise the possibility that
there may be individual variability in the phenotypic re-
sponses to KIF14 overexpression. Although not tested
here, the types of molecular lesions contained within the
primary tumors may partly explain this differential re-
sponse. We have however shown that most of the primary
samples demonstrate dependence on KIF14 expression for
proliferative capacity, indicating that KIF14 may have a
role in promoting OvCa cell survival and tumor growth.
Out of the 29 high-grade serous primary samples re-
ceived, only 11 samples were developed into short-term
cultures. The remaining 18 samples were processed, but
no cells were outgrown/retrieved using our standard cul-
ture protocols [31]. This highlights the inherent difficulty
in the development and maintenance of primary cultures.
Barriers to successful culture include the state of the tumor
tissue prior to processing, (necrosis, hypoxia, excessive tis-
sue manipulations). Our culture protocols incorporate
both a basic culture medium devoid of growth factors that
could artificially promote cell growth, and a trypsinization
procedure to remove fibroblast contamination – however
some tumor cells may require the need of these to adapt
and survive in a 2-dimensional culture environment [31].
None of the 11 samples tested demonstrated any growth
in soft agar (11 samples). These results indicate that
although we have shown that primary OvCa cells may
depend on KIF14 for in vitro proliferation, growth in
anchorage-independent conditions cannot be supported
in these primary short-term derived cultures.
There are several explanations for why these cells did
not grow in agarose culture. One explanation is that the
culture conditions to which the cells were initially exposed
(even though for a relatively short period) changed
the ability of these cells to survive in anchorage-
independent conditions. Although we did not test the in
vivo growth of freshly isolated tumor cells, adaptation of
these cells to 2-dimensional adherent culture conditions
may have altered their inherent tumorigenic behaviours
and reduced the tumor-initiating capacity of these cells.
Furthermore, as mentioned earlier, we found that short-
term cultures of primary high-grade serous OvCa cells
does result in decreased KIF14 expression in comparison
to their primary tumor tissue counterparts (Figure 1), in-
dicating that our culture conditions can promote cell
survival without the need of high oncogene activation
(in this case, high KIF14 expression). This could explainwhy in general, primary OvCa cells exhibited lower KIF14
mRNA expression in comparison to primary tumor ex-
pression after short-term growth in culture.
Another point to consider is that our culture system
does select for epithelial cell populations, and does not
support the growth of stromal, mesenchymal or fibroblas-
tic cells known to exist within the primary tumor micro-
environment [31]; thus this pure epithelial cell population
may demonstrate different tumorigenic behaviours as
compared to cultures within a mixed population of cells.
In fact, tumor-stromal cell interactions have been well
documented to be crucial in pancreatic cancer cell growth
and metastatic behaviours [32], and are also becoming in-
creasingly important in the metastatic behaviour of pri-
mary ovarian cancers [33].
The four most proliferative cases were chosen to test
the model using xenografts. Unfortunately none of these
xenografts were successful in producing tumors. The type
of xenograft that was chosen (subcutaneous xenograft)
could have affected the survival of these cultured cells. Al-
though tumorigenic growth was not observed using this
xenograft method, other methods could be employed
(intrabursal, mammary fat pad injections) to evaluate the
tumorigenic capacity of these derived cell cultures. Alterna-
tively, unpublished data suggest that prolonged exposure to
in vitro growth conditions prevents growth in xenografts.
To date, no publication has described xenografts derived
from primary cells grown in culture, which represents a
major obstacle to this type of research.
Our results indicate that although increases in prolifer-
ative capacity of short-term cultured cells derived from
OvCa patient tumors were seen with KIF14 overexpres-
sion, other changes in carcinogenic signalling pathways
may also be required for survival and growth of these cells
in anchorage-independent conditions. In other words,
in primary tumor cells which possess limited genomic
changes, KIF14 overexpression may not be sufficient to
induce tumor growth in vivo, as compared to established
cell lines, known to have high genomic instability and pos-
sess the capacity to form anchorage-independent colonies
and form subcutaneous tumors. It would be interesting to
evaluate whether combining KIF14 overexpression with
other known genetic and molecular perturbations present
in OvCa (p53, PTEN, PI3K, MAPK) [34,35] would affect
the anchorage-independent properties of these cells.
In summary, we were able to evaluate the effect of KIF14
manipulation on the in vitro growth of short-term primary
OvCa cultures. We determined that most of our short-
term derived primary OvCa cultures were dependent on
KIF14 expression for growth in vitro, but that for a number
of technical reasons, these cells could not demonstrate
growth in vivo. We have thus demonstrated the devel-
opment of a useful and effective in vitro system of gene
manipulation to assess growth properties of primary
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a potential oncogene on proliferative capacity. This method
could also be employed to evaluate responsiveness to thera-
peutic interventions.
Highlights
• We evaluated the potential of selective KIF14 inhibition
in primary high-grade serous patient-derived OvCa cells
• Short-term cultures of primary high-grade serous
demonstrated dependence upon KIF14 expression to
maintain proliferative capacity
• An effective in vitro method to evaluate target gene
manipulation on the proliferative capacity of primary
OvCa cultures was developed.
Additional files
Additional file 1: Figure S1. Expression of KIF14 in primary OvCa cultures
in response to anti-KIF14 shRNA lentivirus transduction. A Representative
sample (6973) was imaged for KIF14 expression using immunofluorescence
microscopy following transduction with either a scrambled shRNA control
(SCR; top panel) or an anti-KIF14 shRNA (LV-816; bottom panel). Images
taken at 14 days post-transduction. Cells were stained with anti-KIF14
antibody (green, left panels) or DAPI to reveal nuclei (blue, right
panels). Magnification, 400X. B Representative immunoblot of 6973 cells
transduced with anti-KIF14 shRNA (LV-816-1 and −2; 1 and 2 represent
2 different transduction experiments), with scrambled shRNA (SCR) or
untransduced (U), assayed 14 days post-transfection. β tubulin, loading
control.
Additional file 2: Figure S2. Expression of EGFP tag in primary OvCa
cultures in response to KIF14 transfection. A Representative sample (6972)
was imaged for KIF14 expression using fluorescence microscopy following
transient transfection with either an empty vector control (pcDNA;
top panel) or a KIF14-EGFP-tagged construct (KIF14-EGFP; bottom
panel). Images taken at 14 days post-transfection. Cells were stained
with anti-KIF14 antibody (top left panel), or visualized by EGFP fluorescence
(bottom left panel), and stained with DAPI to reveal nuclei (blue,
top/bottom left panels). Magnification, 400X. B Representative immunoblot
of 6972 cells transfected with KIF14-EGFP (KIF14-1 and −2; 1 and 2
represent 2 different transfection experiments), with empty vector
(pcDNA) or untransfected (U), assayed 14 days post-transfection. β
tubulin, loading control.
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